Xeris sues Torrent, Rising and others over generic KEVEYIS patent infringement
On October 13, 2026, Xeris Biopharma, through subsidiary Xeris Pharmaceuticals, filed patent infringement lawsuits in federal court in New Jersey against several makers of generic dichlorphenamide, the active ingredient in its KEVEYIS product. The suits follow the grant of U.S. Patent No. 12,758,502, and the company seeks an injunction, monetary and enhanced damages, and attorneys' fees. The filing does not include financial figures, so the effect on shareholders will depend on the outcome of the litigation.
Key points
- Two separate actions filed October 13, 2026, in the U.S. District Court for the District of New Jersey.
- Defendants include Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
- The suits concern U.S. Patent No. 12,758,502, related to the KEVEYIS (dichlorphenamide) product.
- The company seeks a judgment of infringement, injunctive relief, monetary and enhanced damages, attorneys' fees, and costs.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.